ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1661

Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares?

Angela Pakozdi1, Ravindra Rajakariar2, Michael Sheaff3 and Dev Pyne1, 1Rheumatology, Barts Health NHS Trust, London, United Kingdom, 2Renal Medicine, Barts Health NHS Trust, London, United Kingdom, 3Histopathology, Barts Health NHS Trust, London, United Kingdom

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: biopsies, immunosuppressants, lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose Lupus nephritis (LN) is the major cause of morbidity and mortality in patients with systemic lupus erythematosus. The role of repeat kidney biopsies (RB) to guide treatment or to predict outcome and prognosis has been controversial. In this retrospective study we focused on histological characteristics of RBs and aimed to identify any clinical variables useful to predict histological changes. 

Methods In a large single-centre cohort of 257 patients from 1988-2014 with biopsy proven LN, 58 (23%) had two or more biopsies (a total of 68 RBs). LN classes based on glomerular pathology were defined according to the ISN/RPS classification. Clinical and laboratory data were obtained from electronic records of patients.

Results The median time between initial and RB was 33 months [IQR, 15-84]. Caucasians (n=8) had a lower RB rate of 16% compared to blacks (n=37, 33%; p=0.010). Indication for RB was worsening proteinuria (n=38, 71%; of which 23 had associated rising creatinine, 61%), rise in serum creatinine alone (n=6, 11%) and lack of treatment response (n=9, 17%) defined as <50% reduction in proteinuria. At time of RB, 25 (78%) had raised dsDNA, 33 (73%) had low complements. LN class transition occurred in 31 (48%), most commonly from class II or V to III or IV (n=11, 36%). 6 RB (6.8%) showed inactive lesions either due to FSGS or advanced sclerosing LN. 42 (65%) had a change in their treatment regime. Immunosuppression was more likely to be escalated in case of a class switch (87% vs. 38%, p=0.002). The histological transition could not be predicted by any serological or biochemical variables.

Conclusion Over a 1/3 of our LN patients showed histological transition to a more aggressive class, based on which the majority (87%) had treatment escalation. Histological transition could not be predicted by clinical values. Hence, we conclude that RB remains an important tool to guide management of selected patients with LN, in particular those with initial class II or V who flare.


Disclosure:

A. Pakozdi,
None;

R. Rajakariar,
None;

M. Sheaff,
None;

D. Pyne,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-repeat-renal-biopsies-important-in-managing-lupus-nephritis-flares/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology